SlideShare a Scribd company logo
1 of 36
Dr Htet Htet
MBBS, MMedSc
CVS Pharmacology (IV)
Drugs acting on Renin-Angiotensin-Aldosterone System
All rights reserved.
 At the end of the lecture, students should be able to
 List the drugs act on RAA system.
 Explain the physiological role of RAA system.
 Describe the pharmacology of ACEI, ARB and renin
inhibitors.
Learning outline
1. What is RAA system?
2. What are the drugs acting on RAA system?
3. Pharmacology of
a. Renin inhibitor
b. ACEI
c. ARB
d. Aldosterone antagonists.
What is RAA system?
 Renal arterial
pressure
 Sympathetic
stimulation
 Sodium
delivery
A parallel system for angiotensin generation exists in
several other tissues (eg, heart) and may be responsible
for trophic changes such as cardiac hypertrophy.
What are the drugs acting on RAA system?
Pharmacology of drugs
1. Aliskiren (DRI)
2. ACEI
3. ARB
4. Aldosterone antagonists
Aliskiren
 MOA
 Inhibits the activity of renin.
 Effects/Pharmacological action
 Reduces angiotensin I & II and aldosterone.
 Clinical application
 Systemic hypertension
 Route – oral
 Untoward effects – hyperkalaemia, renal impairment, potential
teratogen.
ACEI
 Mechanism of action
 Inhibits ACE (angiotensin converting enzyme) which converts
Ang I to Ang II.
Pharmacological action/effects
Angiotensin
I
ACE
ACEI
 Angiotensin
II

Sympathetic
activation
 Aldosterone
production
Vasodilation
in both
arteries and
veins
 ADH
production
from anterior
pituitary
 Na+ & H2O
reabsorption
from renal
tubules
 K+
retention
 Water
retention
from the
renal tubules
 BP
Causes delay
in cardiac
remodeling
process
Useful in post
myocardial
infarct
patients
Causes delay
in diabetic
nephropathy
Useful in
hypertensive
patients with
nephropathy
 Preload
and
afterload
of the
heart
 Cardiac
workload
Congestiv
e heart
failure
 Due to inhibition in bradykinin breakdown – high level of
bradykinin – leads to cough (untoward effect).
Therapeutic uses
1. Systemic hypertension
2. Hypertensive patients with post MI
3. Hypertensive patients with diabetes mellitus
4. Post MI patients
5. Congestive heart failure
6. Diabetic nephropathy patients (not with chronic renal
failure)
7. Progressive renal insufficiency
 Systemic hypertension
 ACEI are used in hypertension because
 sympathetic activation
Causes vasodilation of both arteries and veins
Decrease sodium and water retention.
 Patients with high renin activity are most effective but all
hypertensive patients can have benefit.
 Hypertensive patients with post MI / post MI patients
 ACEI can delay the cardiac remodeling process and this effect
makes ACEI useful for patients with post MI or hypertensive
patients with post MI.
 Hypertensive patients with diabetes mellitus patients
 particularly useful
 diminish proteinuria and stabilize renal function (even in the absence
of lowering of blood pressure)
 now recommended in diabetes even in the absence of hypertension.
 Congestive heart failure
 Can decrease cardiac workload by arterial and venous dilatation –
(which is useful effect in heart failure) + delay cardiac remodeling
 Therefore, extremely useful in the treatment of heart failure
 It can also reduce the incidence of diabetes in patients with high
cardiovascular risk.
Different preparations of ACEI
 Captopril – effective drug which decreases BP by two actions – 1.
by decreasing Ang II 2. by increasing bradykinin.
 Enalapril is a pro drug, which converts to enalaprilat.
 Lisinopril is a lysine derivative of enalaprilat.
 Benazepril, fosinopril, moexipril, perindopril, quinapril,
ramipril, and trandolapril are other long-acting members of the
class. All are prodrugs, like enalapril, and are converted to the
active agents by hydrolysis, primarily in the liver.
Status of ACEI
 Angiotensin II inhibitors lower blood pressure principally by
decreasing peripheral vascular resistance. Cardiac output and
heart rate are not significantly changed.
 Unlike direct vasodilators, these agents do not result in reflex
sympathetic activation and can be used safely in persons
with ischemic heart disease.
Untoward effects of ACEI
1. Severe hypotension (who are hypovolemic as a result of diuretics,
salt restriction, or gastrointestinal fluid loss)
2. acute renal failure (particularly in patients with bilateral renal
artery stenosis or stenosis of the renal artery of a solitary kidney)
3. Hyperkalemia (more likely to occur in patients with renal
insufficiency or diabetes)
4. dry cough sometimes accompanied by wheezing, and
angioedema (Bradykinin and substance P seem to be responsible)
5. ACE inhibitors are contraindicated during pregnancy because
of the risk of fetal hypotension, anuria, and renal failure,
sometimes associated with fetal malformations or death.
6. Minor toxic effects seen more typically include altered sense of
taste, allergic skin rashes, and drug fever, which may occur in
up to 10% of patients.
7. Captopril, particularly when given in high doses to patients with
renal insufficiency, may cause neutropenia or proteinuria.
Drug interaction
 ACEI + potassium sparing diuretics – can worsen hyperkalaemia.
 ACEI + NSAIDs – may blunt the antihypertensive effect of ACEI.
Angiotensin receptor blockers (ARB)
 Losartan and valsartan were the first marketed blockers of the
angiotensin II type 1 (AT1) receptor.
 Candesartan, eprosartan, irbesartan,telmisartan, and
olmesartan are also available.
Mechanism of action of ARB
 blockers of the angiotensin II type 1 (AT1) receptor.
 have no effect on bradykinin metabolism and are therefore
more selective blockers of angiotensin effects than ACE
inhibitors.
 They also have the potential for more complete inhibition of
angiotensin action compared with ACE inhibitors because there
are enzymes other than ACE that are capable of generating
angiotensin II.
Pharmacological action/effects
Angiotensin
I
ACE
ACEI
 Angiotensin
II

Sympathetic
activation
 Aldosterone
production
Vasodilation
in both
arteries and
veins
 ADH
production
from anterior
pituitary
 Na+ & H2O
reabsorption
from renal
tubules
 K+
retention
 Water
retention
from the
renal tubules
 BP
Causes delay
in cardiac
remodeling
process
Useful in post
myocardial
infarct
patients
Causes delay
in diabetic
nephropathy
Useful in
hypertensive
patients with
nephropathy
 Preload
and
afterload
of the
heart
 Cardiac
workload
Congestiv
e heart
failure
 No inhibition in bradykinin breakdown – less chance of cough
 Angiotensin receptor blockers provide benefits similar to those
of ACE inhibitors in patients with heart failure and chronic
kidney disease.
Adverse effects
 The adverse effects are similar to those described for ACE
inhibitors, including the hazard of use during pregnancy. ***
 Cough and angioedema can occur but are less common with
angiotensin receptor blockers than with ACE inhibitors
Pharmacokinetics of ACEI and ARB
Drug Half-life
(hr)
Bioavailabili
ty
(%)
Dosage requirement in moderate
renal insufficiency
Captopril 2.2 65 Yes
Lisinopril 12 25 Yes
Losartan 1-2 36 No
Drugs that antagonize the aldosterone
action
 Spironolactone, eplerenone
References

More Related Content

What's hot

Anti anginal drugs, uses, mechanism of action, adverse effects
Anti anginal drugs, uses, mechanism of action, adverse effectsAnti anginal drugs, uses, mechanism of action, adverse effects
Anti anginal drugs, uses, mechanism of action, adverse effectsKarun Kumar
 
Renin angiotensin system & drugs
Renin angiotensin system & drugsRenin angiotensin system & drugs
Renin angiotensin system & drugsSurya Prajapat
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsShikha Popali
 
Renin Angiotensin Aldosterone System and its applications
Renin Angiotensin Aldosterone System and its applicationsRenin Angiotensin Aldosterone System and its applications
Renin Angiotensin Aldosterone System and its applicationsDrSahilKumar
 
Antihypertensive mbbs copy
Antihypertensive mbbs   copyAntihypertensive mbbs   copy
Antihypertensive mbbs copyDivya Krishnan
 
Antiarrhythmic drugs
Antiarrhythmic drugs Antiarrhythmic drugs
Antiarrhythmic drugs ajaykumarbp
 
2.2.1 diuretics and antidiuretic drugs
2.2.1 diuretics and antidiuretic drugs2.2.1 diuretics and antidiuretic drugs
2.2.1 diuretics and antidiuretic drugsArunachalam Muthuraman
 
calcium channel blockers
calcium channel blockerscalcium channel blockers
calcium channel blockersDocdhingra
 
Fibrinolytics & antiplatelets
Fibrinolytics & antiplateletsFibrinolytics & antiplatelets
Fibrinolytics & antiplateletsNaser Tadvi
 
Coagulant and anti coagulant
Coagulant and anti coagulantCoagulant and anti coagulant
Coagulant and anti coagulantacademic
 
Histamine and antihistaminic
Histamine and antihistaminicHistamine and antihistaminic
Histamine and antihistaminicNaser Tadvi
 

What's hot (20)

Adrenergic drugs
Adrenergic drugsAdrenergic drugs
Adrenergic drugs
 
Anti anginal drugs, uses, mechanism of action, adverse effects
Anti anginal drugs, uses, mechanism of action, adverse effectsAnti anginal drugs, uses, mechanism of action, adverse effects
Anti anginal drugs, uses, mechanism of action, adverse effects
 
Drugs for heart failure
Drugs for heart failureDrugs for heart failure
Drugs for heart failure
 
Renin angiotensin system & drugs
Renin angiotensin system & drugsRenin angiotensin system & drugs
Renin angiotensin system & drugs
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Renin Angiotensin Aldosterone System and its applications
Renin Angiotensin Aldosterone System and its applicationsRenin Angiotensin Aldosterone System and its applications
Renin Angiotensin Aldosterone System and its applications
 
Antihypertensive mbbs copy
Antihypertensive mbbs   copyAntihypertensive mbbs   copy
Antihypertensive mbbs copy
 
Antiarrhythmic drugs
Antiarrhythmic drugs Antiarrhythmic drugs
Antiarrhythmic drugs
 
Adrenaline pharmacology
Adrenaline pharmacologyAdrenaline pharmacology
Adrenaline pharmacology
 
2.2.1 diuretics and antidiuretic drugs
2.2.1 diuretics and antidiuretic drugs2.2.1 diuretics and antidiuretic drugs
2.2.1 diuretics and antidiuretic drugs
 
calcium channel blockers
calcium channel blockerscalcium channel blockers
calcium channel blockers
 
Fibrinolytics & antiplatelets
Fibrinolytics & antiplateletsFibrinolytics & antiplatelets
Fibrinolytics & antiplatelets
 
COAGULANTS
COAGULANTSCOAGULANTS
COAGULANTS
 
Coagulant and anti coagulant
Coagulant and anti coagulantCoagulant and anti coagulant
Coagulant and anti coagulant
 
Antiplatelet drugs
Antiplatelet drugsAntiplatelet drugs
Antiplatelet drugs
 
Pharmacology of Diuretics
Pharmacology of DiureticsPharmacology of Diuretics
Pharmacology of Diuretics
 
Histamine and antihistaminic
Histamine and antihistaminicHistamine and antihistaminic
Histamine and antihistaminic
 
Antianginal drugs
Antianginal drugsAntianginal drugs
Antianginal drugs
 
Diuretics...
Diuretics...Diuretics...
Diuretics...
 
ADRENERGIC BLOCKERS
ADRENERGIC BLOCKERSADRENERGIC BLOCKERS
ADRENERGIC BLOCKERS
 

Similar to Drugs acting on Renin Angiotensin Aldosterone system

ACE Inhibitors and receptor blockers.pptx
ACE Inhibitors and receptor blockers.pptxACE Inhibitors and receptor blockers.pptx
ACE Inhibitors and receptor blockers.pptxHaider Ali
 
Angiotensin-II Receptor Blocker Update --dr shanjida
Angiotensin-II Receptor Blocker Update --dr shanjidaAngiotensin-II Receptor Blocker Update --dr shanjida
Angiotensin-II Receptor Blocker Update --dr shanjidaFerdous Rafy
 
Ace inhibitors
Ace inhibitorsAce inhibitors
Ace inhibitorsgabarian
 
Reaction Paper On Ramipril
Reaction Paper On RamiprilReaction Paper On Ramipril
Reaction Paper On RamiprilOlga Bautista
 
Drugs used in congestive heart failiure
Drugs used in congestive heart failiureDrugs used in congestive heart failiure
Drugs used in congestive heart failiureRishabhSurana23
 
Antihypertensive drugs.pdf
Antihypertensive drugs.pdfAntihypertensive drugs.pdf
Antihypertensive drugs.pdfAxmedXBullaale
 
Cardiovascular system drugs
Cardiovascular system drugsCardiovascular system drugs
Cardiovascular system drugsKarun Kumar
 
CONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPY
CONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPYCONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPY
CONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPYBobby Prashanth
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsKarun Kumar
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsajaykumarbp
 
Antihypertensives acting on RAAS
Antihypertensives acting on RAASAntihypertensives acting on RAAS
Antihypertensives acting on RAASAnkita Bist
 
ACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptx
ACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptxACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptx
ACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptxDr. Baqir Raza Naqvi
 
Antihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro ReceptorAntihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro ReceptorChetan Prakash
 

Similar to Drugs acting on Renin Angiotensin Aldosterone system (20)

Week 5 Pharma
Week 5 PharmaWeek 5 Pharma
Week 5 Pharma
 
Antihypertensive lecture
Antihypertensive lecture Antihypertensive lecture
Antihypertensive lecture
 
ACE Inhibitors and receptor blockers.pptx
ACE Inhibitors and receptor blockers.pptxACE Inhibitors and receptor blockers.pptx
ACE Inhibitors and receptor blockers.pptx
 
Angiotensin-II Receptor Blocker Update --dr shanjida
Angiotensin-II Receptor Blocker Update --dr shanjidaAngiotensin-II Receptor Blocker Update --dr shanjida
Angiotensin-II Receptor Blocker Update --dr shanjida
 
A2
A2A2
A2
 
Ace inhibitors
Ace inhibitorsAce inhibitors
Ace inhibitors
 
Ras system
Ras systemRas system
Ras system
 
Reaction Paper On Ramipril
Reaction Paper On RamiprilReaction Paper On Ramipril
Reaction Paper On Ramipril
 
Drugs used in congestive heart failiure
Drugs used in congestive heart failiureDrugs used in congestive heart failiure
Drugs used in congestive heart failiure
 
Antihypertensive drugs.pdf
Antihypertensive drugs.pdfAntihypertensive drugs.pdf
Antihypertensive drugs.pdf
 
Cardiovascular system drugs
Cardiovascular system drugsCardiovascular system drugs
Cardiovascular system drugs
 
Angiotensin Converting Enzyme Inhibitors
Angiotensin Converting Enzyme InhibitorsAngiotensin Converting Enzyme Inhibitors
Angiotensin Converting Enzyme Inhibitors
 
AcE Inhibitors in Hypertension
AcE Inhibitors in HypertensionAcE Inhibitors in Hypertension
AcE Inhibitors in Hypertension
 
CONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPY
CONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPYCONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPY
CONGESTIVE HEART FAILURE - DRUGS WITHOUT POSITIVE IONOTROPY
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Antihypertensives acting on RAAS
Antihypertensives acting on RAASAntihypertensives acting on RAAS
Antihypertensives acting on RAAS
 
ACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptx
ACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptxACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptx
ACE Inhibitors + AT1 Receptor blockers, by Baqir Naqvi.pptx
 
Antihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro ReceptorAntihypertensives | Classes of Drugs | Baro Receptor
Antihypertensives | Classes of Drugs | Baro Receptor
 
7.cvs
7.cvs7.cvs
7.cvs
 

More from Dr Htet

Drug therapy of depression
Drug therapy of depression Drug therapy of depression
Drug therapy of depression Dr Htet
 
Whys & Wherefores in clinical pharmacology (1)
Whys & Wherefores in clinical pharmacology (1)Whys & Wherefores in clinical pharmacology (1)
Whys & Wherefores in clinical pharmacology (1)Dr Htet
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers Dr Htet
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers Dr Htet
 
Drug therapy of congestive heart failure
Drug therapy of congestive heart failureDrug therapy of congestive heart failure
Drug therapy of congestive heart failureDr Htet
 
Pharmacology of Organic Nitrates
Pharmacology of Organic Nitrates Pharmacology of Organic Nitrates
Pharmacology of Organic Nitrates Dr Htet
 
Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Dr Htet
 
Antiviral Agents
Antiviral Agents Antiviral Agents
Antiviral Agents Dr Htet
 
Drug Therapy of Depression
Drug Therapy of Depression Drug Therapy of Depression
Drug Therapy of Depression Dr Htet
 
Pharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesPharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesDr Htet
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsDr Htet
 
Pharmacokinetics of oral cavity
Pharmacokinetics of oral cavityPharmacokinetics of oral cavity
Pharmacokinetics of oral cavityDr Htet
 
Introduction to Neuropharmacology
Introduction to Neuropharmacology Introduction to Neuropharmacology
Introduction to Neuropharmacology Dr Htet
 
Anticholinergics Drugs for Optometry
Anticholinergics Drugs for Optometry Anticholinergics Drugs for Optometry
Anticholinergics Drugs for Optometry Dr Htet
 
Cholinergic Drugs and Anticholinesterases in Optometry
Cholinergic Drugs and Anticholinesterases in Optometry Cholinergic Drugs and Anticholinesterases in Optometry
Cholinergic Drugs and Anticholinesterases in Optometry Dr Htet
 
Introduction to ANS Pharmacology
Introduction to ANS Pharmacology Introduction to ANS Pharmacology
Introduction to ANS Pharmacology Dr Htet
 
Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists Dr Htet
 
Drugs and The Liver
Drugs and The Liver Drugs and The Liver
Drugs and The Liver Dr Htet
 
Common Adverse Drug Reactions
Common Adverse Drug ReactionsCommon Adverse Drug Reactions
Common Adverse Drug ReactionsDr Htet
 

More from Dr Htet (19)

Drug therapy of depression
Drug therapy of depression Drug therapy of depression
Drug therapy of depression
 
Whys & Wherefores in clinical pharmacology (1)
Whys & Wherefores in clinical pharmacology (1)Whys & Wherefores in clinical pharmacology (1)
Whys & Wherefores in clinical pharmacology (1)
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers
 
Drug therapy of congestive heart failure
Drug therapy of congestive heart failureDrug therapy of congestive heart failure
Drug therapy of congestive heart failure
 
Pharmacology of Organic Nitrates
Pharmacology of Organic Nitrates Pharmacology of Organic Nitrates
Pharmacology of Organic Nitrates
 
Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia
 
Antiviral Agents
Antiviral Agents Antiviral Agents
Antiviral Agents
 
Drug Therapy of Depression
Drug Therapy of Depression Drug Therapy of Depression
Drug Therapy of Depression
 
Pharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesPharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseases
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
 
Pharmacokinetics of oral cavity
Pharmacokinetics of oral cavityPharmacokinetics of oral cavity
Pharmacokinetics of oral cavity
 
Introduction to Neuropharmacology
Introduction to Neuropharmacology Introduction to Neuropharmacology
Introduction to Neuropharmacology
 
Anticholinergics Drugs for Optometry
Anticholinergics Drugs for Optometry Anticholinergics Drugs for Optometry
Anticholinergics Drugs for Optometry
 
Cholinergic Drugs and Anticholinesterases in Optometry
Cholinergic Drugs and Anticholinesterases in Optometry Cholinergic Drugs and Anticholinesterases in Optometry
Cholinergic Drugs and Anticholinesterases in Optometry
 
Introduction to ANS Pharmacology
Introduction to ANS Pharmacology Introduction to ANS Pharmacology
Introduction to ANS Pharmacology
 
Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists
 
Drugs and The Liver
Drugs and The Liver Drugs and The Liver
Drugs and The Liver
 
Common Adverse Drug Reactions
Common Adverse Drug ReactionsCommon Adverse Drug Reactions
Common Adverse Drug Reactions
 

Recently uploaded

LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingSakthi Kathiravan
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinethanaram patel
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 

Recently uploaded (20)

LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursing
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicine
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 

Drugs acting on Renin Angiotensin Aldosterone system

  • 1. Dr Htet Htet MBBS, MMedSc CVS Pharmacology (IV) Drugs acting on Renin-Angiotensin-Aldosterone System All rights reserved.
  • 2.  At the end of the lecture, students should be able to  List the drugs act on RAA system.  Explain the physiological role of RAA system.  Describe the pharmacology of ACEI, ARB and renin inhibitors.
  • 3. Learning outline 1. What is RAA system? 2. What are the drugs acting on RAA system? 3. Pharmacology of a. Renin inhibitor b. ACEI c. ARB d. Aldosterone antagonists.
  • 4. What is RAA system?  Renal arterial pressure  Sympathetic stimulation  Sodium delivery
  • 5.
  • 6.
  • 7. A parallel system for angiotensin generation exists in several other tissues (eg, heart) and may be responsible for trophic changes such as cardiac hypertrophy.
  • 8. What are the drugs acting on RAA system?
  • 9. Pharmacology of drugs 1. Aliskiren (DRI) 2. ACEI 3. ARB 4. Aldosterone antagonists
  • 10. Aliskiren  MOA  Inhibits the activity of renin.  Effects/Pharmacological action  Reduces angiotensin I & II and aldosterone.  Clinical application  Systemic hypertension  Route – oral  Untoward effects – hyperkalaemia, renal impairment, potential teratogen.
  • 11.
  • 12. ACEI  Mechanism of action  Inhibits ACE (angiotensin converting enzyme) which converts Ang I to Ang II.
  • 14. Angiotensin I ACE ACEI  Angiotensin II  Sympathetic activation  Aldosterone production Vasodilation in both arteries and veins  ADH production from anterior pituitary  Na+ & H2O reabsorption from renal tubules  K+ retention  Water retention from the renal tubules  BP Causes delay in cardiac remodeling process Useful in post myocardial infarct patients Causes delay in diabetic nephropathy Useful in hypertensive patients with nephropathy  Preload and afterload of the heart  Cardiac workload Congestiv e heart failure
  • 15.  Due to inhibition in bradykinin breakdown – high level of bradykinin – leads to cough (untoward effect).
  • 16.
  • 17. Therapeutic uses 1. Systemic hypertension 2. Hypertensive patients with post MI 3. Hypertensive patients with diabetes mellitus 4. Post MI patients 5. Congestive heart failure 6. Diabetic nephropathy patients (not with chronic renal failure) 7. Progressive renal insufficiency
  • 18.  Systemic hypertension  ACEI are used in hypertension because  sympathetic activation Causes vasodilation of both arteries and veins Decrease sodium and water retention.  Patients with high renin activity are most effective but all hypertensive patients can have benefit.
  • 19.  Hypertensive patients with post MI / post MI patients  ACEI can delay the cardiac remodeling process and this effect makes ACEI useful for patients with post MI or hypertensive patients with post MI.  Hypertensive patients with diabetes mellitus patients  particularly useful  diminish proteinuria and stabilize renal function (even in the absence of lowering of blood pressure)  now recommended in diabetes even in the absence of hypertension.
  • 20.  Congestive heart failure  Can decrease cardiac workload by arterial and venous dilatation – (which is useful effect in heart failure) + delay cardiac remodeling  Therefore, extremely useful in the treatment of heart failure  It can also reduce the incidence of diabetes in patients with high cardiovascular risk.
  • 21. Different preparations of ACEI  Captopril – effective drug which decreases BP by two actions – 1. by decreasing Ang II 2. by increasing bradykinin.  Enalapril is a pro drug, which converts to enalaprilat.  Lisinopril is a lysine derivative of enalaprilat.  Benazepril, fosinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril are other long-acting members of the class. All are prodrugs, like enalapril, and are converted to the active agents by hydrolysis, primarily in the liver.
  • 22. Status of ACEI  Angiotensin II inhibitors lower blood pressure principally by decreasing peripheral vascular resistance. Cardiac output and heart rate are not significantly changed.  Unlike direct vasodilators, these agents do not result in reflex sympathetic activation and can be used safely in persons with ischemic heart disease.
  • 23. Untoward effects of ACEI 1. Severe hypotension (who are hypovolemic as a result of diuretics, salt restriction, or gastrointestinal fluid loss) 2. acute renal failure (particularly in patients with bilateral renal artery stenosis or stenosis of the renal artery of a solitary kidney) 3. Hyperkalemia (more likely to occur in patients with renal insufficiency or diabetes) 4. dry cough sometimes accompanied by wheezing, and angioedema (Bradykinin and substance P seem to be responsible)
  • 24. 5. ACE inhibitors are contraindicated during pregnancy because of the risk of fetal hypotension, anuria, and renal failure, sometimes associated with fetal malformations or death. 6. Minor toxic effects seen more typically include altered sense of taste, allergic skin rashes, and drug fever, which may occur in up to 10% of patients. 7. Captopril, particularly when given in high doses to patients with renal insufficiency, may cause neutropenia or proteinuria.
  • 25. Drug interaction  ACEI + potassium sparing diuretics – can worsen hyperkalaemia.  ACEI + NSAIDs – may blunt the antihypertensive effect of ACEI.
  • 26. Angiotensin receptor blockers (ARB)  Losartan and valsartan were the first marketed blockers of the angiotensin II type 1 (AT1) receptor.  Candesartan, eprosartan, irbesartan,telmisartan, and olmesartan are also available.
  • 27. Mechanism of action of ARB  blockers of the angiotensin II type 1 (AT1) receptor.  have no effect on bradykinin metabolism and are therefore more selective blockers of angiotensin effects than ACE inhibitors.  They also have the potential for more complete inhibition of angiotensin action compared with ACE inhibitors because there are enzymes other than ACE that are capable of generating angiotensin II.
  • 29. Angiotensin I ACE ACEI  Angiotensin II  Sympathetic activation  Aldosterone production Vasodilation in both arteries and veins  ADH production from anterior pituitary  Na+ & H2O reabsorption from renal tubules  K+ retention  Water retention from the renal tubules  BP Causes delay in cardiac remodeling process Useful in post myocardial infarct patients Causes delay in diabetic nephropathy Useful in hypertensive patients with nephropathy  Preload and afterload of the heart  Cardiac workload Congestiv e heart failure
  • 30.  No inhibition in bradykinin breakdown – less chance of cough  Angiotensin receptor blockers provide benefits similar to those of ACE inhibitors in patients with heart failure and chronic kidney disease.
  • 31. Adverse effects  The adverse effects are similar to those described for ACE inhibitors, including the hazard of use during pregnancy. ***  Cough and angioedema can occur but are less common with angiotensin receptor blockers than with ACE inhibitors
  • 32. Pharmacokinetics of ACEI and ARB Drug Half-life (hr) Bioavailabili ty (%) Dosage requirement in moderate renal insufficiency Captopril 2.2 65 Yes Lisinopril 12 25 Yes Losartan 1-2 36 No
  • 33. Drugs that antagonize the aldosterone action  Spironolactone, eplerenone
  • 34.
  • 35.